Updated recommendations on the use of ruxolitinib for the treatment of myelofibrosis.
Timothy DevosDominik SelleslagNikki GranacherViolaine HavelangeFleur Samantha BenghiatPublished in: Hematology (Amsterdam, Netherlands) (2022)
Based on new data and clinical experience, the panel of experts discussed ruxolitinib treatment in Belgian myelofibrosis patients with a focus on dose optimization/monitoring, adverse events, and interruption/rechallenge management.
Keyphrases